Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medistem Laboratories and Orcrist Bio have entered a collaborative agreement to co-develop therapies based upon their respective core intellectual properties.
Subscribe to our email newsletter
This includes utilization of Medistem’s newly discovered Endometrial Regenerative Cell population and Orcrist’s recently licensed HYC750 technology.
Gary Voncina, CEO of Orcrist Bio, said: “The potential for collaboration around Orcrist’s stem cell mobilization technology and Medistem’s core intellectual property could lead to ground-breaking advancements in the commercialization of stem cell products.”